Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit.
The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson’s atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress’ probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE.

View full story: https://www.biocentury.com/article/660033

#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech

00:01 - Sponsor Message: CBRE
01:15 - Novartis Buying Myricx
08:01 - U.K. Regulation
14:44 - DeGette & FDA Reform
21:51 - Parkinson's Atlas Insights
29:39 - China Trials Probe

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text